Advancements in neuroscience, AI, and bioengineering are unlocking new possibilities for neurotechnologies. Investors are paying attention.

Alex Morgan of Khosla Ventures is an MD, PhD, physicist, and one of the most active investors in neurotech startups. He's backed companies harnessing neuromodulation for varied applications - from sleep (Somnee) to depression (Flow) to motor recovery (Syncron). 

In this episode, Alex shares an insider's overview of the neurotech landscape. We discuss when neurotech solutions make more sense than traditional pharma. Alex reveals which brain technologies excite him most, and why.

We also unpack key business strategy questions. When should startups pursue the consumer route versus FDA approval? What does Alex look for in neurotech founders on the cutting edge?

This episode is for founders, investors, clinicians, and researchers interested in understanding the cutting edge of neurotech and how it will become an integral part to the future of our mental health.